The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 05, 2021
Filed:
Sep. 07, 2018
Applicant:
Novo Nordisk A/s, Bagsvaerd, DK;
Inventors:
Ida Hilden, Frederiksberg, DK;
Bernd Peschke, Slagelse, DK;
Jens Breinholt, Dyssegaerd, DK;
Mikael Kofod-Hansen, Broenshoej, DK;
Assignee:
Novo Nordisk Healthcare AG, Zurich, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/48 (2006.01); A61K 47/68 (2017.01); C07K 16/28 (2006.01); C07K 14/47 (2006.01); C12N 9/64 (2006.01); C07K 14/745 (2006.01); C12N 9/96 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/4846 (2013.01); A61K 47/6815 (2017.08); A61K 47/6849 (2017.08); C07K 14/4703 (2013.01); C07K 14/745 (2013.01); C07K 16/2803 (2013.01); C12N 9/644 (2013.01); C12N 9/6437 (2013.01); C12N 9/96 (2013.01); C12Y 304/21021 (2013.01); C12Y 304/21022 (2013.01); A61K 38/00 (2013.01); C07K 2299/00 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/41 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C07K 2319/21 (2013.01);
Abstract
Described are procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing procoagulant proteins; polynucleotides that encode fusion proteins and cells that expresses them. Furthermore, described are procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with such procoagulant proteins.